Stock data
Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics, Inc. (DMRA) reported net income of -US$209.84M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$210.87M | -US$209.84M | — |
| 2024 | — | — | -US$22.26M | -US$21.44M | — |
| 2023 | — | — | -US$39.91M | -US$38.35M | — |
| 2022 | — | — | -US$61.21M | -US$61.62M | — |
| 2021 | — | — | -US$52.23M | -US$51.75M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$31.17M | — |
| 2026-03-31 | — | -US$27.78M | — |
| 2025-12-31 | — | -US$200.74M | — |
| 2025-09-30 | — | -US$3.13M | — |
| 2025-06-30 | — | -US$3.44M | — |
| 2025-03-31 | — | -US$2.53M | — |
| 2024-12-31 | — | -US$6.74M | — |
| 2024-09-30 | — | -US$3.88M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.